Peptide-targeted Radionuclide Therapy for Melanoma

Overview

Journal Crit Rev Oncol Hematol

Specialty Hematology

Date 2008 Apr 5

PMID 18387816

Citations 23

Authors

Yubin Miao

Thomas P Quinn

Affiliations

Soon will be listed here.

Abstract

Melanocortin-1 receptor (MC1-R) and melanin are two attractive melanoma-specific targets for peptide-targeted radionuclide therapy for melanoma. Radiolabeled peptides targeting MC1-R/melanin can selectively and specifically target cytotoxic radiation generated from therapeutic radionuclides to melanoma cells for cell killing, while sparing the normal tissues and organs. This review highlights the recent advances of peptide-targeted radionuclide therapy of melanoma targeting MC1-R and melanin. The promising therapeutic efficacies of 188Re-(Arg(11))CCMSH (188Re-[Cys(3,4,10), D-Phe(7),Arg(11)]-alpha-MSH(3-13)), 177Lu- and 212Pb-labeled DOTA-Re(Arg(11))CCMSH (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-[ReO-(Cys(3,4,10), D-Phe(7), Arg(11))]-alpha-MSH(3-13)) and 188Re-HYNIC-4B4 (188Re-hydrazinonicotinamide-Tyr-Glu-Arg-Lys-Phe-Trp-His-Gly-Arg-His) in preclinical melanoma-bearing models demonstrate an optimistic outlook for peptide-targeted radionuclide therapy for melanoma. Peptide-targeted radionuclide therapy for melanoma will likely contribute in an adjuvant setting, once the primary tumor has been surgically removed, to treat metastatic deposits and for treatment of end-stage disease. The lack of effective treatments for metastatic melanoma and end-stage disease underscores the necessity to develop and implement new treatment strategies, such as peptide-targeted radionuclide therapy.

Citing Articles

The application of radionuclide therapy for breast cancer.

Musket A, Davern S, Elam B, Musich P, Moorman J, Jiang Y Front Nucl Med. 2024; 3:1323514.

PMID: 39355029 PMC: 11440853. DOI: 10.3389/fnume.2023.1323514.

MC1R and melanin-based molecular probes for theranostic of melanoma and beyond.

Shi H, Cheng Z Acta Pharmacol Sin. 2022; 43(12):3034-3044.

PMID: 36008707 PMC: 9712491. DOI: 10.1038/s41401-022-00970-y.

Incidental Synchronous Tc-HYNIC-TOC Avid Lesion of the Neck in a Patient with Metastatic Melanoma: A Metastatic Lymph Node or a Carotid Body Tumor Masquerading As a Lymph Node?.

Roshanravan V, Soltani E, Hasanzadeh Haddad E, Sadeghi R, Sahebkari A, Mottaghi M Asia Ocean J Nucl Med Biol. 2022; 10(2):138-141.

PMID: 35800421 PMC: 9205846. DOI: 10.22038/AOJNMB.2021.59706.1415.

Bifunctional chelators for radiorhenium: past, present and future outlook.

Melis D, Burgoyne A, Ooms M, Gasser G RSC Med Chem. 2022; 13(3):217-245.

PMID: 35434629 PMC: 8942221. DOI: 10.1039/d1md00364j.

Advances in Receptor-Targeted Radiolabeled Peptides for Melanoma Imaging and Therapy.

Miao Y, Quinn T J Nucl Med. 2020; 62(3):313-318.

PMID: 33277401 PMC: 8049342. DOI: 10.2967/jnumed.120.243840.

References

Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P . Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999; 26(11):1439-47. View

Teunissen J, Kwekkeboom D, de Jong M, Esser J, Valkema R, Krenning E . Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol. 2005; 19(4):595-616. DOI: 10.1016/j.bpg.2005.04.001. View

Larsen R, Akabani G, Welsh P, Zalutsky M . The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. Radiat Res. 1998; 149(2):155-62. View

Miao Y, Whitener D, Feng W, Owen N, Chen J, Quinn T . Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconjug Chem. 2003; 14(6):1177-84. DOI: 10.1021/bc034069i. View

Sawyer T, Staples D, Castrucci A, Hadley M, Cody W, Hruby V . Alpha-melanocyte stimulating hormone message and inhibitory sequences: comparative structure-activity studies on melanocytes. Peptides. 1990; 11(2):351-7. DOI: 10.1016/0196-9781(90)90092-j. View

Chen J, Cheng Z, Hoffman T, Jurisson S, Quinn T . Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res. 2000; 60(20):5649-58. View

Valkema R, de Jong M, Bakker W, Breeman W, Kooij P, Lugtenburg P . Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med. 2002; 32(2):110-22. DOI: 10.1053/snuc/2002.31025. View

Sgouros G, Ballangrud A, Jurcic J, McDevitt M, Humm J, Erdi Y . Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med. 1999; 40(11):1935-46. View

Wagner J, Schauwecker D, Davidson D, Logan T, Coleman 3rd J, Hutchins G . Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer. 2005; 104(3):570-9. DOI: 10.1002/cncr.21189. View

10.

Eberle A, Verin V, Solca F, Siegrist W, Kuenlin C, Bagutti C . Biologically active monoiodinated alpha-MSH derivatives for receptor binding studies using human melanoma cells. J Recept Res. 1991; 11(1-4):311-22. DOI: 10.3109/10799899109066410. View

11.

Garg P, Alston K, Welsh P, Zalutsky M . Enhanced binding and inertness to dehalogenation of alpha-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate. Bioconjug Chem. 1996; 7(2):233-9. DOI: 10.1021/bc960001+. View

12.

Ginj M, Hinni K, Tschumi S, Schulz S, Maecke H . Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters. J Nucl Med. 2005; 46(12):2097-103. View

13.

Dennis L . Analysis of the melanoma epidemic, both apparent and real: data from the 1973 through 1994 surveillance, epidemiology, and end results program registry. Arch Dermatol. 1999; 135(3):275-80. DOI: 10.1001/archderm.135.3.275. View

14.

Heppeler A, Froidevaux S, Eberle A, Maecke H . Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem. 2000; 7(9):971-94. DOI: 10.2174/0929867003374516. View

15.

de Jong M, Bakker W, Krenning E, Breeman W, van der Pluijm M, Bernard B . Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. 1997; 24(4):368-71. DOI: 10.1007/BF00881807. View

16.

de Jong M, Breeman W, Bernard B, Bakker W, Schaar M, van Gameren A . [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 2001; 92(5):628-33. DOI: 10.1002/1097-0215(20010601)92:5<628::aid-ijc1244>3.0.co;2-l. View

17.

McDevitt M, Ma D, Lai L, Simon J, Borchardt P, Frank R . Tumor therapy with targeted atomic nanogenerators. Science. 2001; 294(5546):1537-40. DOI: 10.1126/science.1064126. View

18.

Miao Y, Owen N, Whitener D, Gallazzi F, Hoffman T, Quinn T . In vivo evaluation of 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer. 2002; 101(5):480-7. DOI: 10.1002/ijc.10640. View

19.

Behr T, Behe M, Lohr M, Sgouros G, Angerstein C, Wehrmann E . Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur J Nucl Med. 2000; 27(7):753-65. DOI: 10.1007/s002590000272. View

20.

Boerman O, Oyen W, Corstens F . Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur J Nucl Med. 2001; 28(10):1447-9. DOI: 10.1007/s002590100597. View